The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Market Value Of The Rituximab Biosimilars Market Projected To Expand During 2026–2030?
The rituximab biosimilars market has shown rapid expansion in recent years. This market is anticipated to increase from $3.42 billion in 2025 to $3.84 billion in 2026, recording a compound annual growth rate (CAGR) of 12.5%. Factors contributing to its historical growth include the substantial cost of originator rituximab, the increasing prevalence of non-Hodgkin’s lymphoma, a rising incidence of chronic lymphocytic leukemia, enhanced awareness in autoimmune disease management, and limited availability of advanced biologics.
The rituximab biosimilars market size is projected to undergo rapid expansion in the upcoming years. It is expected to reach $6.26 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. This anticipated growth during the forecast period is attributable to the launch of new biosimilar formulations, the broader availability of subcutaneous delivery options, increasing adoption in developing markets, rising government and insurance backing for biosimilars, and their integration with hospital and specialty pharmacy programs. Key trends for the forecast period include the increasing uptake of rituximab biosimilars for oncology and autoimmune diseases, the expansion of subcutaneous administration and pre-filled delivery systems, a growing preference for cost-effective monoclonal antibody alternatives, the rising use of antibody-drug conjugates (ADCs) in targeted therapy, and enhanced hospital and retail pharmacy distribution channels.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3430&type=smp
What Influential Factors Are Boosting The Rituximab Biosimilars Market Demand?
The increasing occurrence of non-hodgkin’s lymphoma (NHL) is projected to boost the expansion of the rituximab biosimilars market in the future. Non-Hodgkin’s lymphoma is defined as a form of cancer originating in white blood cells, particularly lymphocytes, which are essential components of the immune system. Its growing prevalence is driven by higher incidence rates, especially among older demographics and as a result of lifestyle and environmental influences. Rituximab Biosimilars effectively target and eliminate CD20-positive B cells, contributing to a reduction in tumor burden, better regulation of the immune system, and offering a more accessible and economical treatment choice for individuals with non-Hodgkin’s lymphoma (NHL), thus improving overall therapeutic results and patient quality of life. For example, the American Cancer Society, a US-based cancer advocacy organization, reported in January 2024 that around 80,620 individuals (44,590 men and 36,030 women) were anticipated to receive a diagnosis of non-Hodgkin lymphoma, alongside an estimated 20,140 deaths (11,780 men and 8,360 women). The lifetime probability of developing this cancer stands at approximately 1 in 42 for men and 1 in 52 for women. Consequently, the increasing prevalence of non-Hodgkin’s lymphoma is propelling the expansion of the rituximab biosimilars market.
How Is The Rituximab Biosimilars Market Distributed Across Key Segments?
The rituximab biosimilars market covered in this report is segmented –
1) By Route Of Administration: Subcutaneous, Intravenous
2) By Application: Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Mail Order
Subsegments:
1) By Subcutaneous: Pre-filled Syringes, Injection Pens
2) By Intravenous: IV Infusion Solutions, IV Push Formulations
Which Trends Are Supporting The Evolution Of The Rituximab Biosimilars Market?
Key companies operating within the rituximab biosimilars market are prioritizing the development of novel products through deliberate collaborations. This strategy aims to improve accessibility and provide more economical treatment options for individuals suffering from various immunological and oncological conditions. Engaging with established partners assists companies in accelerating their commercialization efforts, harnessing collective expertise in regulatory clearances and distribution, and effectively introducing biosimilars to the market, thereby expanding patient access and market penetration. For instance, Dr. Reddy’s Laboratories partnered with Fresenius Kabi in July 2023 to commercialize its proposed rituximab biosimilar in the US. This joint effort is intended to introduce a biosimilar version of rituximab, offering patients a more affordable and readily available treatment choice. The introduction of a rituximab biosimilar in the United States holds the potential to broaden access to this crucial therapeutic option for patients dealing with conditions such as rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.
Who Are The Firms Contributing To The Rituximab Biosimilars Market Ecosystem?
Major companies operating in the rituximab biosimilars market are Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., Cadila Pharmaceuticals, Hetero Drugs Limited, Dr. Reddy’s Laboratories, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Reliance Life Sciences India, Zenotech Laboratories, Celltrion, Biocad, MABION S.A., Amgen, Teva Pharmaceuticals, Celltrion Healthcare, Coherus BioSciences, Aryogen Biopharma, TR-Pharm, Hikma Pharmaceuticals plc.
Access The Complete Rituximab Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report
Which Region Has The Strongest Presence In The Rituximab Biosimilars Market?
North America was the largest region in the rituximab biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the rituximab biosimilars market report during the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Rituximab Biosimilars Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=3430&type=smp
Browse Through More Reports Similar to the Global Rituximab Biosimilars Market 2026, By The Business Research Company
Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
Oncology Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Oral Biologics And Biosimilars Market 2026
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model